Clinical Trial

A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of mRNA-1283 and mRNA-1273 (variant formulations) in adults 50 to 64 years of age without high risk factors for severe COVID-19.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-04-29
Trial Details
NCT Number NCT07266558
Lead Sponsor ModernaTX, Inc.
Conditions SARS-CoV-2
Enrollment 30,000 participants
Start Date 2025-11-26
Primary Completion 2027-06-16 (estimated)
Study Completion 2027-06-16 (estimated)
Updated on ClinicalTrials.gov 2026-04-28